AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant
Authors: Dotti, G Rambaldi, A Fiocchi, R Motta, T Torre, G Viero, P Gridelli, B Barbui, T
Citation: G. Dotti et al., Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant, HAEMATOLOG, 86(6), 2001, pp. 618-623
Pharmacokinetic study of the new cyclosporin-A formulation (Neoral (TM)) in adult allogeneic bone marrow transplant recipients
Authors: Dotti, G Gaspari, F Caruso, R Perico, N Remuzzi, G Barbui, T Rambaldi, A
Citation: G. Dotti et al., Pharmacokinetic study of the new cyclosporin-A formulation (Neoral (TM)) in adult allogeneic bone marrow transplant recipients, HAEMATOLOG, 86(3), 2001, pp. 311-315
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia
Authors: Finazzi, G Barbui, T
Citation: G. Finazzi et T. Barbui, Efficacy and safety of hydroxyurea in patients with essential thrombocythemia, PATH BIOL, 49(2), 2001, pp. 167-169
Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome
Authors: Galli, M Barbui, T
Citation: M. Galli et T. Barbui, Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome, CLIN CHEM, 47(6), 2001, pp. 985-987
Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma
Authors: Cortelazzo, S Rambaldi, A Rossi, A Oldani, E Ghielmin, M Benedetti, F Tarella, C Zaglio, F Vitolo, U Di Nicola, M Pogliani, E Cavalli, F Gianni, AM Barbui, T
Citation: S. Cortelazzo et al., Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma, BR J HAEM, 114(2), 2001, pp. 333-341
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
Authors: Golay, J Lazzari, M Facchinetti, V Bernasconi, S Borleri, G Barbui, T Rambaldi, A Introna, M
Citation: J. Golay et al., CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59, BLOOD, 98(12), 2001, pp. 3383-3389
Early application of anthracyclines in adult acute lymphoblastic leukemia (ALL)
Authors: Bassan, R Rohatiner, AZS Lerede, T Carter, M Di Bona, E Pogliani, E Rossi, G Fabris, P Morandi, S Lambertenghi-Deliliers, G Casula, P Vespignani, M Lister, TA Barbui, T
Citation: R. Bassan et al., Early application of anthracyclines in adult acute lymphoblastic leukemia (ALL), HEMAT BLOOD, 40, 2001, pp. 402-413
Preliminary results of a risk-oriented program for B-lineage adult acute lymphoblastic leukemia (ALL): The collaborative Italian study 08/96
Authors: Bassan, R Rambaldi, A Pogliani, E Rossi, G Fabris, P Morandi, S Casula, P Lambertenghi-Deliliers, G Vespignani, M Lerede, T Personeni, A Bellavita, P Barbui, T
Citation: R. Bassan et al., Preliminary results of a risk-oriented program for B-lineage adult acute lymphoblastic leukemia (ALL): The collaborative Italian study 08/96, HEMAT BLOOD, 40, 2001, pp. 419-425
Prognostic factors in Philadelphia plus BCR-ABL plus acute lymphoblastic leukemia
Authors: Bassan, R Rohatiner, AZ Di Bona, E Lerede, T Carter, M Rambaldi, A Pogliani, E Rossi, G Fabris, P Morandi, S Lambertenghi-Deliliers, G Lister, TA Barbui, T
Citation: R. Bassan et al., Prognostic factors in Philadelphia plus BCR-ABL plus acute lymphoblastic leukemia, HEMAT BLOOD, 40, 2001, pp. 426-431
Split-course high-dose ARA-C plus idarubicin and multidrug blockade by short cyclosporin-A infusion for refractory acute myeloid leukemia
Authors: Bassan, R Lerede, T Chiodini, B Rossi, A Buelli, M Barbui, T
Citation: R. Bassan et al., Split-course high-dose ARA-C plus idarubicin and multidrug blockade by short cyclosporin-A infusion for refractory acute myeloid leukemia, HEMAT BLOOD, 40, 2001, pp. 438-445
Thrombosis and malignancy - Preface
Authors: Falanga, A Barbui, T
Citation: A. Falanga et T. Barbui, Thrombosis and malignancy - Preface, ACT HAEMAT, 106(1-2), 2001, pp. 5-5
Coagulopathy of acute promyelocytic leukemia
Authors: Falanga, A Barbui, T
Citation: A. Falanga et T. Barbui, Coagulopathy of acute promyelocytic leukemia, ACT HAEMAT, 106(1-2), 2001, pp. 43-51
Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies
Authors: Introna, M Barbui, AM Bambacioni, F Casati, C Gaipa, G Borleri, G Bernasconi, S Barbui, T Golay, J Biondi, A Rambaldi, A
Citation: M. Introna et al., Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies, HUM GENE TH, 11(4), 2000, pp. 611-620
Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG
Authors: Michiels, JJ Barbui, T Finazzi, G Fuchtman, SM Kutti, J Rain, JD Silver, RT Tefferi, A Thiele, J
Citation: Jj. Michiels et al., Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG, LEUK LYMPH, 36(3-4), 2000, pp. 239-253
High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia
Authors: Rohatiner, AZS Bassan, R Raimondi, R Amess, JAL Arnott, S Personen, A Rodeghiero, F Barbui, T Bradburn, MJ Carter, M Lister, TA
Citation: Azs. Rohatiner et al., High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia, ANN ONCOL, 11(8), 2000, pp. 1007-1015
Trends in mortality from leukemia in subsequent age groups
Authors: Levi, F Lucchini, F Negri, E Barbui, T La Vecchia, C
Citation: F. Levi et al., Trends in mortality from leukemia in subsequent age groups, LEUKEMIA, 14(11), 2000, pp. 1980-1985
Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation
Authors: Spinelli, O Giussani, U Borleri, G Lazzari, M Michelato, A Dotti, G Barbui, T Rambaldi, A
Citation: O. Spinelli et al., Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation, HAEMATOLOG, 85(11), 2000, pp. 1153-1157
Lupus anticoagulants and thrombosis: Clinical association of different coagulation and immunologic tests
Authors: Galli, M Dlott, J Norbis, F Ruggeri, L Cler, L Triplett, DA Barbui, T
Citation: M. Galli et al., Lupus anticoagulants and thrombosis: Clinical association of different coagulation and immunologic tests, THROMB HAEM, 84(6), 2000, pp. 1012-1016
Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant
Authors: Dotti, G Fiocchi, R Motta, T Gamba, A Gotti, E Gridelli, B Borleri, G Manzoni, C Viero, P Remuzzi, G Barbui, T Rambaldi, A
Citation: G. Dotti et al., Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant, TRANSPLANT, 69(5), 2000, pp. 827-833
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study
Authors: Chopra, R Eaton, JD Grassi, A Potter, M Shaw, B Salat, C Neumeister, P Finazzi, G Iacobelli, M Bowyer, K Prentice, HG Barbui, T
Citation: R. Chopra et al., Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study, BR J HAEM, 111(4), 2000, pp. 1122-1129
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial
Authors: Finazzi, G Ruggeri, M Rodeghiero, F Barbui, T
Citation: G. Finazzi et al., Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial, BR J HAEM, 110(3), 2000, pp. 577-583
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups
Authors: Sanz, MA Lo Coco, F Martin, G Avvisati, G Rayon, C Barbui, T Diaz-Mediavilla, J Fioritoni, G Gonzalez, JD Liso, V Esteve, J Ferrara, F Bolufer, P Bernasconi, C Gonzalez, M Rodeghiero, F Colomer, D Petti, MC Ribera, JM Mandelli, F
Citation: Ma. Sanz et al., Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups, BLOOD, 96(4), 2000, pp. 1247-1253
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
Authors: Falanga, A Marchetti, M Evangelista, V Vignoli, A Licini, M Balicco, M Manarini, S Finazzi, G Cerietti, C Barbui, T
Citation: A. Falanga et al., Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera, BLOOD, 96(13), 2000, pp. 4261-4266
Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients
Authors: Bacigalupo, A Bruno, B Saracco, P Di Bona, E Locasciulli, A Locatelli, F Gabbas, A Dufour, C Arcese, W Testi, G Broccia, G Carotenuto, M Coser, P Barbui, T Leoni, P Ferster, A
Citation: A. Bacigalupo et al., Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients, BLOOD, 95(6), 2000, pp. 1931-1934
Management of thrombocytopenia in Hughes syndrome
Authors: Galli, M Barbui, T
Citation: M. Galli et T. Barbui, Management of thrombocytopenia in Hughes syndrome, HUGHES SYNDROME: ANTIPHOSPHOLIPID SYNDROME, 2000, pp. 408-418
Risultati: 1-25 | 26-45